Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa study of glatiramer acetate (MyeloXen) for treatment of multiple sclerosis in Russia

Trial Profile

Phase IIa study of glatiramer acetate (MyeloXen) for treatment of multiple sclerosis in Russia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Multiple sclerosis vaccine (Primary)
  • Indications Multiple sclerosis
  • Focus First in man; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 01 Apr 2016 Results published in a PJSC Pharmsynthez media release.
    • 01 Apr 2016 Status changed from active, no longer recruiting to completed, according to a PJSC Pharmsynthez media release.
    • 21 Nov 2014 Dosing of patients completed, according to a Xenetic Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top